TSE:4519Pharmaceuticals
Assessing Chugai Pharmaceutical (TSE:4519) Valuation After ELEVIDYS Gene Therapy Launch In Japan
Why ELEVIDYS matters for Chugai Pharmaceutical (TSE:4519)
Chugai Pharmaceutical (TSE:4519) has just launched ELEVIDYS in Japan as the first gene therapy for Duchenne muscular dystrophy, following its listing on the National Health Insurance price list.
This product milestone expands Chugai’s rare disease gene therapy offering and introduces a new treatment option for eligible DMD patients, supported by data from the global Phase 3 EMBARK study.
See our latest analysis for Chugai...